Language selection

Search

Patent 3224856 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 3224856
(54) English Title: NOVEL CRYSTALLINE FORMS OF SUGAMMADEX
(54) French Title: NOUVELLES FORMES CRISTALLINES DE SUGAMMADEX
Status: Granted and Issued
Bibliographic Data
(51) International Patent Classification (IPC):
  • C08B 37/16 (2006.01)
  • A61K 31/724 (2006.01)
  • A61P 23/00 (2006.01)
(72) Inventors :
  • LARPENT, PATRICK (Switzerland)
  • STUEBER, DIRK (United States of America)
  • VARSOLONA, RICHARD J. (United States of America)
(73) Owners :
  • WERTHENSTEIN BIOPHARMA GMBH
  • MERCK SHARP & DOHME LLC
(71) Applicants :
  • WERTHENSTEIN BIOPHARMA GMBH (Switzerland)
  • MERCK SHARP & DOHME LLC (United States of America)
(74) Agent: MCCARTHY TETRAULT LLP
(74) Associate agent:
(45) Issued: 2024-05-07
(86) PCT Filing Date: 2021-09-08
(87) Open to Public Inspection: 2022-03-17
Examination requested: 2023-12-19
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): Yes
(86) PCT Filing Number: PCT/US2021/049352
(87) International Publication Number: WO 2022055918
(85) National Entry: 2023-12-19

(30) Application Priority Data:
Application No. Country/Territory Date
63/076,135 (United States of America) 2020-09-09

Abstracts

English Abstract

The present disclosure provides a novel crystalline forms of sugammadex, designated herein as crystalline form Type 7 of sugammadex, crystalline form Type 10 of sugammadex, crystalline form Type 12 of sugammadex, and crystalline form Type 13 of sugammadex, pharmaceutical compositions thereof, and methods for their use in the reversal of neuromuscular blockade induced by rocuronium bromide or by vecuronium bromide in adults undergoing surgery.


French Abstract

La présente divulgation concerne de nouvelles formes cristallines de sugammadex, désignées dans la description comme forme cristalline de type 7 de sugammadex, forme cristalline de type 10 de sugammadex, forme cristalline de type 12 de sugammadex et forme cristalline de type 13 de sugammadex, des compositions pharmaceutiques associées et des méthodes pour leur utilisation dans l'inversion du blocage neuromusculaire induit par le bromure de rocuronium ou par le bromure de vécuronium chez l'adulte subissant une intervention chirurgicale.

Claims

Note: Claims are shown in the official language in which they were submitted.


CLAIMS
1. A crystalline form Type 7 of sugammadex characterized by a powder x-ray
diffraction pattern obtained using Cu K alpha radiation with at least peaks at
diffraction angles
degrees 2 theta (+/- 0.2 ) of: 5.64; 6.07; 6.83; 7.19; 10.72; 13.64; 20.71.
2. The crystalline form Type 7 of sugammadex according to claim 1, further
characterized by a powder x-ray diffraction pattern with at least peaks at
diffraction angles
degrees 2 theta (+/- 0.2 ) of: 5.64; 6.07; 6.83; 7.19; 9.25; 9.88; 10.72;
13.64; 14.84; 16.39; 16.97;
17.81; 19.16; 19.31; 19.65; 20.71; 21.90.
3. The crystalline form Type 7 of sugammadex according to claim 2, further
characterized by a powder x-ray diffraction pattern with at least peaks at
diffraction angles
degrees 2 theta (+/- 0.2 ) of: 5.64; 6.07; 6.83; 7.19; 9.25; 9.88; 10.72;
13.64; 14.84; 15.17; 16.39;
16.97; 17.81; 18.27; 19.16; 19.31; 19.65; 20.71; 21.14; 21.90; 22.63; 23.20.
4. The crystalline form Type 7 of sugammadex according to any one of claims
1-3,
for use in the preparation of an injectable composition comprising sugammadex
and a
pharmaceutically-acceptable diluent for the reversal of neuromuscular blockade
induced by
recuronium bromide and vecuronium bromide in adults undergoing surgery.
5. Use of sugammadex in the manufacture of a medicament to reverse
neuromuscular blockade in an adult subject undergoing surgery, said sugammadex
comprising
crystalline form Type 7 characterized by a powder x-ray diffraction pattern
obtained using Cu K
alpha radiation with at least peaks at diffraction angles degrees 2 theta (+/-
0.2 ) of 5.64; 6.07;
6.83; 7.19; 10.72; 13.64; 20.71.
6. The use according to claim 5, wherein the crystalline form Type 7 is
further
characterized by a powder x-ray diffraction pattern with at least peaks at
diffraction angles
degrees 2 theta (+/- 0.2 ) of 5.64; 6.07; 6.83; 7.19; 9.25; 9.88; 10.72;
13.64; 14.84; 16.39; 16.97;
17.81; 19.16; 19.31; 19.65; 20.71; 21.90.
14
Date Recue/Date Received 2024-03-08

7. The use according to claim 6, wherein the crystalline form Type 7 is
further
characterized by a powder x-ray diffraction pattern with at least peaks at
diffraction angles
degrees 2 theta (+/- 0.2 ) of 5.64; 6.07; 6.83; 7.19; 9.25; 9.88; 10.72;
13.64; 14.84; 15.17; 16.39;
16.97; 17.81; 18.27; 19.16; 19.31; 19.65; 20.71; 21.14; 21.90; 22.63; 23.20.
8. The use according to any one of claims 5-7, wherein the neuromuscular
blockade
was induced by at least one of recuronium bromide and vecuronium bromide.
9. The use according to any one of claims 5-8, wherein the medicament is in
the
form of powder.
10. A solution for injection, comprising the medicament as defined in claim
9.
11. A method for preparing a solution for injection, comprising adding a
liquid
pharmaceutically-acceptable diluent to the medicament as defined in claim 9.
12. A solution for injection, comprising the medicament as defined in any
one of
claims 5-7.
13. A solution for injection, comprising the crystalline form Type 7 of
sugammadex
as defined in any one of claims 1-3.
14. The solution of claim 13, further comprising one or more
pharmaceutically-
acceptable diluents.
15. A drug substance comprising about 5% to about 100% by weight of the
crystalline form Type 7 of sugammadex as defined in any one of claims 1-3.
16. A drug substance comprising about 10% to about 100% by weight of the
crystalline form Type 7 of sugammadex as defined in any one of claims 1-3.
Date Recue/Date Received 2024-03-08

17. A drug substance comprising about 25% to about 100% by weight of the
crystalline form Type 7 of sugammadex as defined in any one of claims 1-3.
18. A drug substance comprising about 50% to about 100% by weight of the
crystalline form Type 7 of sugammadex as defined in any one of claims 1-3.
19. A drug substance comprising about 75% to about 100% by weight of the
crystalline faun Type 7 of sugammadex as defined in any one of claims 1-3.
20. A pharmaceutical composition comprising a therapeutically-effective
amount of
the crystalline form Type 7 of sugammadex as defined in any one of claims 1-3,
and at least one
pharmaceutically-acceptable diluent, for use in the reversal of neuromuscular
blockade induced
by recuronium bromide and vecuronium bromide in adults undergoing surgery.
21. Use of sugammadex to reverse neuromuscular blockade in a patient
undergoing
surgery, wherein the sugammadex comprises crystalline form Type 7 of
sugammadex as defined
in any one of claims 1-3.
22. The crystalline form Type 7 of sugammadex according to any one of
claims 1-3,
for use in the reversal of neuromuscular blockade in a patient undergoing
surgery.
23. The crystalline form Type 7 of sugammadex as defined in claim 22,
wherein the
patient is an adult.
24. The crystalline form Type 7 of sugammadex as defined in claim 22 or 23,
wherein
the neuromuscular blockage was induced by recuronium bromide and vecuronium
bromide.
25. The crystalline form Type 7 of sugammadex according to any one of
claims 1-3
for use in a method of manufacturing a medicament for reversing neuromuscular
blockade in
patients undergoing surgery.
16
Date Recue/Date Received 2024-03-08

26. The crystalline form Type 7 of sugammadex as defined in claim 25,
wherein the
patients are adult patients.
27. The crystalline form Type 7 of sugammadex as defined in claim 25 or 26,
wherein
the neuromuscular blockade was induced by at least one of recuronium bromide
and vecuronium
bromide.
28. A medicament prepared by a method of manufacturing as defined in any
one of
claims 25-27, said medicament comprising sugammadex as a pharmaceutically-
active ingredient.
29. Sugammadex wet-cake comprising the crystalline form Type 7 of
sugammadex
according to any one of claims 1-3.
30. A sterile pharmaceutical composition comprising the crystalline form
Type 7 of
sugammadex as defined in any one of claims 1-3 and at least one
pharmaceutically-acceptable
diluent.
17
Date Recue/Date Received 2024-03-08

Description

Note: Descriptions are shown in the official language in which they were submitted.


CA 03224856 2023-12-19
WO 2022/055918
PCT/US2021/049352
TITLE OF THE INVENTION
NOVEL CRYSTALLINE FORMS OF SUGAMMADEX
FIELD OF THE INVENTION
The present disclosure provides novel crystalline forms of sugammadex,
designated herein as
crystalline form Type 7 of sugammadex, crystalline form Type 10 of sugammadex,
crystalline
foini Type 12 of sugammadex, and crystalline form Type 13 of sugammadex,
pharmaceutical
compositions thereof, and methods for their use in the reversal of
neuromuscular blockade
induced by recuronium bromide and yecuronium bromide in adults undergoing
surgery
BACKGROUND OF THE INVENTION
Sugammadex is a modified cyclodextrin haying the following structure:
NaO-
0
Na0
Sce0.7ili 0 :Ho =
- (KSOH
8
H01)
OH 0 0
ok0
0 OH
p
0
NaeIC-5
ONa
o 0(NICJI-b /-1
S
Na0
0
sugammadex
Sugammadex was approved in 2008 by the EMEA and in 2015 by the USFDA (and
elsewhere) for the reversal of neuromuscular blockade induced by rocuronium
bromide and
vecuronium bromide in adults undergoing surgery. It is administered
intravenously by injection
in the form of a sterile solution under the brand name BRIDION . Sugammadex is
disclosed in
W02001/040316, published June 7, 2001, together with a method for its
synthesis. An
improved synthesis of sugammadex is disclosed in PCT International Patent
Application No.
W02019/236436, filed June 03, 2019. Other methods of producing sugammadex are
also
disclosed in the art. Once produced, the active ingredient is typically
isolated as a wet cake and
then dried under vacuum to obtain a powder meeting purity and residual solvent
specifications.
The powder is then dissolved in water for injection, the pH adjusted, and the
resulting solution is
filtered and filled into vials, sterilized and stored for use.
1

CA 03224856 2023-12-19
WO 2022/055918
PCT/US2021/049352
SUMMARY OF THE INVENTION
In one aspect, the present disclosure provides novel crystalline forms of
sugammadex. In
one embodiment, there is provided crystalline form type 7 of sugammadex. In
another
embodiment, there is provided crystalline form type 10 of sugammadex. In
another embodiment,
there is provided crystalline form type 12 of sugammadex. In another
embodiment, there is
provided crystalline form type 13 of sugammadex.
In another aspect, the present disclosure provides methods for the use of each
of the
aforementioned crystalline forms of sugammadex in the preparation of a
medicament for use in
the reversal of neuromuscular blockade induced by rocuronium bromide and
vecuronium
bromide in adults undergoing surgery in accordance with its approved label.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graph of a Powder X-Ray Diffraction ("PXRD") pattern of sugammadex
Type
7 crystalline form, generated using the equipment and methods described
herein. The graph plots
the intensity of the peaks as defined by counts per second versus the
diffraction angle 2 theta
(20) in degrees.
FIG. 2 is a graph of a Powder X-Ray Diffraction ("PXRD") pattern of sugammadex
Type
10 crystalline form, generated using the equipment and methods described
herein. The graph
plots the intensity of the peaks as defined by counts per second versus the
diffraction angle 2
theta (20) in degrees.
FIG. 3 is a graph of a Powder X-Ray Diffraction ("PXRD") pattern of sugammadex
Type
12 crystalline form, generated using the equipment and methods described
herein. The graph
plots the intensity of the peaks as defined by counts per second versus the
diffraction angle 2
theta (20) in degrees.
FIG. 4 is a graph of a Powder X-Ray Diffraction ("PXRD") pattern of sugammadex
Type
13 crystalline form, generated using the equipment and methods described
herein. The graph
plots the intensity of the peaks as defined by counts per second versus the
diffraction angle 2
theta (20) in degrees.
DETAILED DESCRIPTION OF THE INVENTION
DEFINITIONS
The terms used herein have their ordinary meaning and the meaning of such
terms is
independent at each occurrence thereof That notwithstanding and except where
stated otherwise,
2

the following definitions apply throughout the specification and claims.
C means degrees Celsius
FIG (or FIG. or Fig. or Fig or fig. or fig) means Figure (or figure) and
refers to the
corresponding figure
g means gram (or grams)
mL means milliliter (or milliliters)
"PXRD" is an abbreviation for powder x-ray diffraction
CRYSTALLINE FORMS OF SUGAMMADEX
The crystalline forms of sugammadex described herein may be prepared according
to the
procedures described below. For each procedure, starting quantities of
sugammadex may be
obtained from any suitable synthesis, including those described in PCT
Publication No.
W02001/040316, published June 07, 2001; W02019/236436, filed June 07, 2018 and
U.S.
Provisional Application No. 62/737140, Attorney Docket No. 24604, filed
September 27, 2018.
PXRD
As those of ordinary skill in the art readily appreciate, the physical
characteristics of a
crystal may be effectively characterized by powder x-ray diffraction (PXRD)
analysis. Such
characterizations may be used to distinguish such crystals from other
crystals. For each of the
crystalline forms of sugammadex described herein, PXRD analysis was completed
on a wet cake
sample since drying the material leads to significant loss of crystallinity
and to form change.
PXRD data reported herein were acquired on a Bruker D8 Advance System
configured in the
Bragg-Brentano configuration and equipped with a Cu radiation source with
monochromatization to Ka achieved using a nickel filter. A fixed slit optical
configuration was
employed for data acquisition. Data were acquired between 3 and 40 20 and a
step size of
0.018 . Samples were prepared by gently pressing the samples onto a shallow
cavity zero
background silicon holder. Wet cake samples were covered with Kapton
(polyimide film,
DuPont, USA) foil in order to maintain the wet-sample-condition throughout
data collection.
Those skilled in the art will recognize that the measurements of the PXRD peak
locations
for a given crystalline form of the same compound will vary within a margin of
error. The
margin of error for the 2-theta values measured as described herein is
typically +/- 0.2 20.
Variability can depend on such factors as the system, methodology, sample, and
conditions used
3
Date Recue/Date Received 2024-03-08

CA 03224856 2023-12-19
WO 2022/055918
PCT/US2021/049352
for measurement. As will also be appreciated by the skilled crystallographer,
the intensities of
the various peaks reported in the figures herein may vary due to a number of
factors such as
orientation effects of crystals in the x-ray beam, the purity of the material
being analyzed, and/or
the degree of crystallinity of the sample. The skilled crystallographer also
will appreciate that
measurements using a different wavelength will result in different shifts
according to the Bragg-
Brentano equation. Such further PXRD patterns generated by use of alternative
wavelengths are
considered to be alternative representations of the PXRD patterns of the
crystalline material of
the present disclosure and as such are within the scope of the present
disclosure.
Preparative Example 1: Crystalline Form Type 1 of Sugammadex
Crystalline form Type 1 of sugammadex was prepared as follows:
1 g of sugammadex was added to 10 mL of a methanol/water mixture with a 10:1
ratio by
volume at 25 C and while applying magnetic stirring, resulting in a slurry.
The slurry was kept
at ambient temperature while stirring for 20 hours. A wet cake sample was
produced by
centrifuging an aliquot of the slurry to a wet paste. PXRD analysis of the wet
cake produced the
Type 1 pattern.
Preparative Example 2: Crystalline Form Type 11 of Sugammadex
Crystalline form Type 11 of sugammadex was prepared as follows:
30 g of Sugammadex was dissolved in 90 ml purified water and the solution
filtered
through a lab glass frit filter. The solution was transferred into a clean 1L
glass reactor equipped
with an overhead stirrer. The solution was heated to 40 C while stirring at
200 rpm. 350 ml of
Me0H was added linearly over 70 min at what stage primary nucleation of Type-1
was
observed. The agitation was increased to 350 rpm and the batch seeded with
Type 2 particles
triggering turnover of the entire batch to Type 2 within minutes. 550 mL of
Me0H were finally
added linearly over 110 min. The batch was cooled to 23 C over 1 h and further
aged 1 h. The
freshly crystallized batch of Type-2 was filtered on a Rosenmund pocket filter
and displace-
washed with 6V of a 86:4:10 (v:v:v) Et0H:MeOH:Water mixture. The resulting
cake was then
dried under a dry Nitrogen flow at 50 C for a minimum of 18 hours (h). PXRD
analysis of the
dried cake produced the Type 11 pattern.
CRYSTALLINE FORM TYPE 7 OF SUGAMMADEX
Crystalline form Type 7 of sugammadex was prepared as follows:
500 mg of sugammadex Type-1 was added to 5 mL of a ethanol/water/methanol
mixture
4

CA 03224856 2023-12-19
WO 2022/055918
PCT/US2021/049352
with a respective 86:10:4 ratio by volume at 25 C and while applying magnetic
stirring, resulting
in a slurry. The slurry was kept at ambient temperature while stirring for 12
hours. A wet cake
sample was produced by centrifuging an aliquot of the slurry to a wet paste.
PXRD analysis of
the wet cake produces the Type 7 pattern.
Physical characterization of crystalline form Type 7 of sugammadex:
A PXRD pattern of crystalline form Type 7 of sugammadex generated using the
equipment and procedures described above is displayed in FIG. 1. Thus, in
another aspect, there
is provided a crystalline form Type 7 of sugammadex characterized by a powder
x-ray
diffraction pattern substantially as shown in FIG. 1.
The intensity of the peaks (y-axis is in counts per second) were plotted
versus the 2 theta
angle (x-axis is in degrees 2 theta). In addition, the data were plotted with
detector counts
normalized for the collection time per step versus the 2-theta angle. Peak
locations (on the 2-
theta x-axis) consistent with these profiles are displayed in Table 1 (+/- 0.2
2 theta). The
locations of these PXRD peaks are characteristic of the crystalline form Type
7 of sugammadex.
.. Thus, in another aspect, crystalline form Type 7 of sugammadex is
characterized by a powder x-
ray diffraction pattern having each of the peak positions listed in Table 1,
+/- 0.2 2-theta.
Table 1: Diffraction peaks and corresponding d-spacings for crystalline form
Type 7 of
sugammadex
Position [ Two
Diagnostic Peak
Peak Number d-spacing [A] Rel. Int. [%]
Theta] Set
1 5.64 15.66 48.22 1
.
2 6.07 14.55 42.56 1
3 6.83 12.93 27.54 1
4 7.19 12.28 27.55 1
5 9.25 9.55 35.54 2
6 9.88 8.94 29.53 2
7 10.72 8.25 27.92 1
8 13.64 6.49 59.32 1
9 14.84 5.96 39.05 2
10 15.17 5.84 28.93 3
11 16.39 5.40 39.96 2
12 16.97 5.22 66.27 2
13 17.81 4.98 58.58 2
14 18.27 4.85 43.98 3
15 19.16 4.63 65.59 2
16 19.31 4.59 63.33 2
17 19.65 4.51 72.44 2
18 20.71 4.29 100.00 1
19 21.14 4.20 57.91 3
5

CA 03224856 2023-12-19
WO 2022/055918
PCT/US2021/049352
Position [ Two
Diagnostic Peak
Peak Number d-spacing [A] Rel. Int. [%]
Theta] Set
20 21.90 4.06 65.35 2
21 22.63 3.93 49.89 3
22 23.20 3.85 35.69 3
In a further aspect, the PXRD peak locations displayed in Table 1 and/or FIG.
1 most
characteristic of crystalline form Type 7 of sugammadex can be selected and
grouped as
"diagnostic peak sets" to conveniently distinguish this crystalline form from
others. Selections
of such characteristic peaks are set out in Table 1 in the column labeled
Diagnostic Peak Set.
Thus, in another aspect, there is provided a crystalline form Type 7 of
sugammadex
characterized by a powder x-ray diffraction pattern comprising each of the 2-
theta values listed
in Diagnostic Peak Set 1 in Table 1, +/- 0.2 2-theta.
In another aspect, there is provided a crystalline form Type 7 of sugammadex
characterized by a powder x-ray diffraction pattern comprising each of the 2-
theta values listed
in Diagnostic Peak Set 2 in Table 1, +/- 0.2 2-theta.
In another aspect, there is provided a crystalline form Type 7 of sugammadex
characterized by a powder x-ray diffraction pattern comprising each of the 2-
theta values listed
in Diagnostic Peak Set 3 in Table 1, +/- 0.2 2-theta.
A further aspect of the disclosure is realized and characterized by a powder x-
ray
diffraction pattern with at least peaks at diffraction angles degrees 2 theta
(+/- 0.2 ) of
Diagnostic Peak Set 1 plus Set 2. A further aspect of the disclosure is
realized and characterized
by a powder x-ray diffraction pattern with at least peaks at diffraction
angles degrees 2 theta (+/-
0.2 ) of Diagnostic Peak Set 1 plus Set 2 plus Set 3. Still another aspect of
the disclosure is
realized where there are at least 3 peaks of Diagnostic Peak Set 1. Another
aspect of the
disclosure is realized where there are at least 4 peaks of Diagnostic Peak Set
1. Another aspect of
the disclosure is realized where there are at least 5 peaks of Diagnostic Peak
Set 1. Another
aspect of the disclosure is realized where there are at least 6 peaks of
Diagnostic Peak Set 1.
Another aspect of the disclosure is realized where there are at least 7 peaks
of Diagnostic Peak
Set 1. Another aspect of the disclosure is realized where there are at least 3
peaks of Diagnostic
Peak Set 1 and 2. Another aspect of the disclosure is realized where there are
at least 3 peaks of
Diagnostic Peak Set 1 and 2 and 1 of Set 3.
CRYSTALLINE FORM TYPE 10 OF SUGAMMADEX
6

CA 03224856 2023-12-19
WO 2022/055918
PCT/US2021/049352
Crystalline form Type 10 of sugammadex was prepared as follows:
In a 1L glass reactor, 30 g of sugammadex were added to 90 mL of water at 25
C while
applying overhead stirring at 200 rpm, resulting in a clear solution. Under
continued overhead
stirring at 200 rpm, the solution was heated to 40 C and then kept at these
conditions for 10 min.
Subsequently, 450 mL of methanol were added at constant rate over two hours
while overhead
stiffing at 200 rpm. The batch was then aged for 6 days at 300 rpm overhead
stirring, triggering
crystallization of large particles. An additional 453 mL of Me0H were added
linearly over 3h
while overhead stirring. The freshly crystallized batch of Type 3 was filtered
on a glass filter and
displace-washed with 3V of a 86:4:10 Et0H:MeOH:Water mixture by volume. The
resulting wet
cake was then quickly transferred to a 100 mL reactor and slurry-washed in 3V
of a 86:4:10
Et0H:MeOH:Water by volume under overhead stirring (350 rpm, 23 C) for 8 days.
A wet cake
sample was produced by centrifuging an aliquot of the slurry to a wet paste.
PXRD analysis of
the wet cake produces the Type 10 pattern.
Physical characterization of crystalline form Type 10 of sugammadex:
A PXRD pattern of crystalline form Type 10 of sugammadex generated using the
equipment and procedures described above is displayed in FIG. 2. Thus, in
another aspect, there
is provided a crystalline form Type 10 of sugammadex characterized by a powder
x-ray
diffraction pattern substantially as shown in FIG. 2.
The intensity of the peaks (y-axis is in counts per second) were plotted
versus the 2-theta
angle (x-axis is in degrees 2 theta). In addition, the data were plotted with
detector counts
normalized for the collection time per step versus the 2-theta angle. Peak
locations (on the 2-
theta x-axis) consistent with these profiles are displayed in Table 2 (+/- 0.2
2 theta). The
locations of these PXRD peaks are characteristic of the crystalline form Type
10 of
sugammadex. Thus, in another aspect, crystalline form Type 10 of sugammadex is
characterized
by a powder x-ray diffraction pattern having each of the peak positions listed
in Table 2, +/- 0.2
2-theta.
Table 2: Diffraction peaks and corresponding d-spacings for crystalline form
Type 10 of
sugammadex
Position [ Two
Diagnostic Peak
Peak Number d-spacing [A] Rel. Int. [NI
Theta] Set
1 3.61 24.48 3.77 3
2 5.98 14.76 56.27 1
3 8.45 10.46 100.00 1
4 13.94 6.35 5.84 3
5 15.38 5.76 3.22 3
7

CA 03224856 2023-12-19
WO 2022/055918
PCT/US2021/049352
Position r Two
Diagnostic Peak
Peak Number d-spacing [A] Rel. Int. [%]
Theta] Set
6 16.76 5.28 21.76 2
7 17.75 4.99 56.84 1
8 18.55 4.78 7.88 3
9 18.92 4.69 6.80 3
20.08 4.42 11.78 2
11 21.30 4.17 60.58 1
12 22.11 4.02 4.11 3
13 22.67 3.92 7.75 3
In a further aspect, the PXRD peak locations displayed in Table 2 and/or FIG.
2 most
characteristic of crystalline form Type 10 of sugammadex can be selected and
grouped as
"diagnostic peak sets" to conveniently distinguish this crystalline form from
others. Selections
5 of such characteristic peaks are set out in Table 2 in the column labeled
Diagnostic Peak Set.
Thus, in another aspect, there is provided a crystalline form Type 10 of
sugammadex
characterized by a powder x-ray diffraction pattern comprising each of the 2-
theta values listed
in Diagnostic Peak Set 1 in Table 2, +/- 0.2 2-theta.
In another aspect, there is provided a crystalline form Type 10 of sugammadex
10 characterized by a powder x-ray diffraction pattern comprising each of
the 2-theta values listed
in Diagnostic Peak Set 2 in Table 2, +/- 0.2 2-theta.
In another aspect, there is provided a crystalline form Type 10 of sugammadex
characterized by a powder x-ray diffraction pattern comprising each of the 2-
theta values listed
in Diagnostic Peak Set 3 in Table 2, +/- 0.2 2-theta.
A further aspect of the disclosure is realized and characterized by a powder x-
ray
diffraction pattern with at least peaks at diffraction angles degrees 2 theta
(+/- 0.2 ) of
Diagnostic Peak Set 1 plus Set 2, A further aspect of the disclosure is
realized and characterized
by a powder x-ray diffraction pattern with at least peaks at diffraction
angles degrees 2 theta (+/-
0.2 ) of Diagnostic Peak Set 1 plus Set 2 plus Set 3. Still another aspect of
the disclosure is
realized where there are at least 2 peaks of Diagnostic Peak Set 1. Another
aspect of the
disclosure is realized where there are at least 3 peaks of Diagnostic Peak Set
1. Another aspect of
the disclosure is realized where there are at least 4 peaks of Diagnostic Peak
Set 1. Another
Another aspect of the disclosure is realized where there are at least 3 peaks
of Diagnostic Peak
Set 1 and 1 peak of Diagnostic Peak 2. Another aspect of the disclosure is
realized where there
are at least 3 peaks of Diagnostic Peak Set 1 and 1 of Diagnostic Peak Set 2
and 1 of Diagnostic
Peak Set 3.
8

CA 03224856 2023-12-19
WO 2022/055918
PCT/US2021/049352
CRYSTALLINE FORM TYPE 12 OF SUGAMMADEX
Crystalline form Type 12 of sugammadex was prepared as follows:
A solution of sugammadex in water with a concentration of 200 mg/mL was
prepared.
The solution was heated to 60 C and the water slowly evaporated, producing a
white powder. A
dry sample was produced after the water had evaporated. PXRD analysis of the
dry sample
produced the Type 12 pattern.
Physical characterization of crystalline form Type 12 of sugammadex:
A PXRD pattern of crystalline fot ______________________________________ m
Type 12 of sugammadex generated using the
equipment and procedures described above is displayed in FIG. 3. Thus, in
another aspect, there
is provided a crystalline form Type 12 of sugammadex characterized by a powder
x-ray
diffraction pattern substantially as shown in FIG. 3.
The intensity of the peaks (y-axis is in counts per second) were plotted
versus the 2-theta
angle (x-axis is in degrees 2 theta). In addition, the data were plotted with
detector counts
normalized for the collection time per step versus the 2-theta angle. Peak
locations (on the 2-
theta x-axis) consistent with these profiles are displayed in Table 3 (+/- 0.2
2 theta). The
locations of these PXRD peaks are characteristic of the crystalline form Type
12 of
sugammadex. Thus, in another aspect, crystalline form Type 12 of sugammadex is
characterized
by a powder x-ray diffraction pattern having each of the peak positions listed
in Table 3, +/- 0.2
2-theta.
Table 3: Diffraction peaks and corresponding d-spacings for crystalline form
Type 12 of
sugammadex
Position [ Two Diagnostic
Peak
Peak Number d-spacing [A] Rel. Int. rol
Theta] Set
1 4.60 19.21 13.63 2
2 5.50 16.07 14.57 2
3 6.40 13.81 36.33 1
4 7.55 11.70 100.00 1
5 8.12 10.88 9.87 2
6 9.06 9.75 6.03 3
7 10.00 8.84 11.70 2
8 10.43 8.48 11.37 2
9 11.94 7.41 11.05 2
10 12.17 7.26 31.55 1
11 12.59 7.03 17.66 2
12 12.84 6.89 20.52 2
13 13.79 6.41 6.25 3
14 14.75 6.00 4.29 3
15 15.27 5.80 5.60 3
9

CA 03224856 2023-12-19
WO 2022/055918
PCT/US2021/049352
Position [O Two
Diagnostic Peak
Peak Number d-spacing [A] Rel. Int. r/o]
Theta] Set
16 15.92 5.56 20.51 2
17 16.40 5.40 14.38 2
18 16.94 5.23 12.60 2
19 17.12 5.17 13.29 2
20 17.65 5.02 14.38 2
21 18.17 4.88 19.82 2
22 18.62 4.76 9.96 2
. .
23 19.28 4.60 12.23 2
24 20.20 4.39 7.20 3
25 20.49 4.33 9.09 2
26 21.10 4.21 5.25 3
27 21.43 4.14 6.65 3
28 22.16 4.01 9.10 2
29 22.52 3.94 7.73 3
30 22.67 3.92 8.25 3
31 22.97 3.87 8.23 3
32 24.16 3.68 6.51 3
33 24.63 3.61 5.97 3
34 37.07 2.42 17.47 2
In a further aspect, the PXRD peak locations displayed in Table 3 and/or FIG.
3 most
characteristic of crystalline form Type 12 of sugammadex can be selected and
grouped as
"diagnostic peak sets" to conveniently distinguish this crystalline form from
others. Selections
of such characteristic peaks are set out in Table 3 in the column labeled
Diagnostic Peak Set.
Thus, in another aspect, there is provided a crystalline form Type 12 of
sugammadex
characterized by a powder x-ray diffraction pattern comprising each of the 2-
theta values listed
in Diagnostic Peak Set 1 in Table 3, +/- 0.2 2-theta.
In another aspect, there is provided a crystalline form Type 12 of sugammadex
characterized by a powder x-ray diffraction pattern comprising each of the 2-
theta values listed
in Diagnostic Peak Set 2 in Table 3, +/- 0.2 2-theta.
In another aspect, there is provided a crystalline form Type 12 of sugammadex
characterized by a powder x-ray diffraction pattern comprising each of the 2-
theta values listed
in Diagnostic Peak Set 3 in Table 3, +/- 0.2 2-theta.
A further aspect of the disclosure is realized and characterized by a powder x-
ray
diffraction pattern with at least peaks at diffraction angles degrees 2 theta
(+/- 0.2 ) of
Diagnostic Peak Set 1 plus Set 2. A further aspect of the disclosure is
realized and characterized

CA 03224856 2023-12-19
WO 2022/055918
PCT/US2021/049352
by a powder x-ray diffraction pattern with at least peaks at diffraction
angles degrees 2 theta (+1-
0.2 ) of Diagnostic Peak Set 1 plus Set 2 plus Set 3. Still another aspect of
the disclosure is
realized where there are at least 1 peaks of Diagnostic Peak Set I. Another
aspect of the
disclosure is realized where there are at least 2 peaks of Diagnostic Peak Set
1. Another aspect of
the disclosure is realized where there are at least 3 peaks of Diagnostic Peak
Set 1. Another
aspect of the disclosure is realized where there are at least 2 peaks of
Diagnostic Peak Set 1 and
3 peaks of Diagnostic Peak 2. Another aspect of the disclosure is realized
where there are at
least 2 peaks of Diagnostic Peak Set 1, 4 peaks of Diagnostic Peak 2 and 3 of
Diagnostic Peak
Set 3.
CRYSTALLINE FORM TYPE 13 OF SUGAMMADEX
Crystalline form Type 13 of sugammadex was prepared as follows:
A 1 g sample of dried Sugammadex Type 111 was placed in a humidity chamber
exhibiting
75% relative humidity at 25 C for 24 hours. PXRD analysis of the dry cake
after 24 hours
produced the Type 13 pattern.
Physical characterization of crystalline form Type 13 of sugammadex:
A PXRD pattern of crystalline form Type 13 of sugammadex generated using the
equipment and procedures described above is displayed in FIG. 4. Thus, in
another aspect, there
is provided a crystalline form Type 13 of sugammadex characterized by a powder
x-ray
diffraction pattern substantially as shown in FIG. 4.
The intensity of the peaks (y-axis is in counts per second) were plotted
versus the 2-theta
angle (x-axis is in degrees 2 theta). In addition, the data were plotted with
detector counts
normalized for the collection time per step versus the 2-theta angle. Peak
locations (on the 2-
theta x-axis) consistent with these profiles are displayed in Table 4 (+/- 0.2
2 theta). The
locations of these PXRD peaks are characteristic of the crystalline form Type
13 of
sugammadex. Thus, in another aspect, crystalline form Type 13 of sugammadex is
characterized
by a powder x-ray diffraction pattern having each of the peak positions listed
in Table 4, +/- 0.2
2-theta.
Table 4: Diffraction peaks and corresponding d-spacings for crystalline form
Type 13 of
sugammadex
Position [ Two
Diagnostic Peak
Peak Number d-spacing [A] Rel. Int. [%]
Theta] Set
1 6.83 12.94 11.45 2
2 10.12 8.74 30.89 1
11

CA 03224856 2023-12-19
WO 2022/055918
PCT/US2021/049352
Position r Two
Diagnostic Peak
Peak Number d-spacing [A] Rel. Int. [%]
Theta] Set
3 10.72 8.25 13.45 3
4 11.37 7.78 14.79 3
13.90 6.37 26.92 1
6 14.59 6.07 36.09 1
7 16.32 5.43 52.60 1
8 16.73 5.30 77.09 1
9 17.26 5.14 100.00 1
18.39 4.82 55.94 1
11 19.42 4.57 70.29 1
12 20.86 4.26 49.54 1
13 21.70 4.09 32.53 3
14 22.12 4.02 52.63 3
22.52 3.95 51.04 3
16 22.98 3.87 41.30 3
17 23.34 3.80 40.57 3
In a further aspect, the PXRD peak locations displayed in Table 4 and/or FIG.
4 most
characteristic of crystalline form Type 13 of sugammadex can be selected and
grouped as
"diagnostic peak sets" to conveniently distinguish this crystalline form from
others. Selections
5 of such characteristic peaks are set out in Table 4 in the column labeled
Diagnostic Peak Set.
Thus, in another aspect, there is provided a crystalline form Type 13 of
sugammadex
characterized by a powder x-ray diffraction pattern comprising each of the 2-
theta values listed
in Diagnostic Peak Set 1 in Table 4, +/- 0.2 2-theta.
In another aspect, there is provided a crystalline forin Type 13 of sugammadex
10 characterized by a powder x-ray diffraction pattern comprising each of
the 2-theta values listed
in Diagnostic Peak Set 2 in Table 4, +/- 0.2 2-theta.
In another aspect, there is provided a crystalline form Type 13 of sugammadex
characterized by a powder x-ray diffraction pattern comprising each of the 2-
theta values listed
in Diagnostic Peak Set 3 in Table 4, +/- 0.2 2-theta.
15 A further
aspect of the disclosure is realized and characterized by a powder x-ray
diffraction pattern with at least peaks at diffraction angles degrees 2 theta
(+/- 0.2 ) of
Diagnostic Peak Set 1 plus Set 2. A further aspect of the disclosure is
realized and characterized
by a powder x-ray diffraction pattern with at least peaks at diffraction
angles degrees 2 theta (+1-
0.2 ) of Diagnostic Peak Set 1 plus Set 2 plus Set 3. Still another aspect of
the disclosure is
realized where there are at least 3 peaks of Diagnostic Peak Set 1. Another
aspect of the
disclosure is realized where there are at least 4 peaks of Diagnostic Peak Set
1. Another aspect of
12

CA 03224856 2023-12-19
WO 2022/055918
PCT/US2021/049352
the disclosure is realized where there are at least 5 peaks of Diagnostic Peak
Set 1. Another
aspect of the disclosure is realized where there are at least 6 peaks of
Diagnostic Peak Set 1.
Another aspect of the disclosure is realized where there are at least 7 peaks
of Diagnostic Peak
Set 1. Another aspect of the disclosure is realized where there are at least 8
peaks of Diagnostic
Peak Set 1. Another aspect of the disclosure is realized where there are at
least 9 peaks of
Diagnostic Peak Set 1. Another aspect of the disclosure is realized where
there are at least 3
peaks of Diagnostic Peak Set 1 and one of Diagnostic Peak set 2. Another
aspect of the
disclosure is realized where there are at least 3 peaks of Diagnostic Peak Set
1, one of Diagnostic
Peak Set 2 and 3 of Diagnostic Peak Set 3.
PREPARATION OF DRUG PRODUCT
Crystallized Type 7, Type 10, Type 12 and Type 13 forms of sugammadex were
prepared
as described above, then isolated as a wet cake and then dried to obtain a
powder meeting purity
and residual solvent specifications. The drug product is then produced by a
formulation and
filling process. The dried sugammadex powder is dissolved in water for
injection and the pH
adjusted to 7.5. The resulting solution is then filtered and filled into
vials, stoppered and capped.
The bulk drug product is then terminally sterilized and stored for use.
13

Representative Drawing
A single figure which represents the drawing illustrating the invention.
Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Maintenance Fee Payment Determined Compliant 2024-08-08
Maintenance Request Received 2024-08-08
Inactive: Grant downloaded 2024-05-07
Grant by Issuance 2024-05-07
Letter Sent 2024-05-07
Inactive: Grant downloaded 2024-05-07
Inactive: Cover page published 2024-05-06
Pre-grant 2024-03-26
Inactive: Final fee received 2024-03-26
Letter Sent 2024-03-25
Notice of Allowance is Issued 2024-03-25
Inactive: Approved for allowance (AFA) 2024-03-21
Inactive: Q2 passed 2024-03-21
Amendment Received - Voluntary Amendment 2024-03-08
Amendment Received - Response to Examiner's Requisition 2024-03-08
Inactive: Cover page published 2024-02-01
Examiner's Report 2024-01-23
Inactive: Report - No QC 2024-01-16
Inactive: IPC removed 2024-01-15
Inactive: IPC assigned 2024-01-15
Inactive: IPC removed 2024-01-15
Inactive: IPC removed 2024-01-15
Inactive: IPC removed 2024-01-15
Inactive: IPC assigned 2024-01-15
Inactive: First IPC assigned 2024-01-15
Letter sent 2024-01-09
Advanced Examination Determined Compliant - paragraph 84(1)(a) of the Patent Rules 2024-01-09
Letter sent 2024-01-04
Priority Claim Requirements Determined Compliant 2024-01-04
Common Representative Appointed 2024-01-04
Request for Priority Received 2024-01-04
Inactive: IPC assigned 2024-01-04
Inactive: IPC assigned 2024-01-04
Inactive: IPC assigned 2024-01-04
Inactive: IPC assigned 2024-01-04
Inactive: IPC assigned 2024-01-04
Application Received - PCT 2024-01-04
Inactive: First IPC assigned 2024-01-04
Letter Sent 2024-01-04
All Requirements for Examination Determined Compliant 2023-12-19
National Entry Requirements Determined Compliant 2023-12-19
Request for Examination Requirements Determined Compliant 2023-12-19
Inactive: Advanced examination (SO) fee processed 2023-12-19
Inactive: Advanced examination (SO) 2023-12-19
Application Published (Open to Public Inspection) 2022-03-17

Abandonment History

There is no abandonment history.

Maintenance Fee

The last payment was received on 2023-12-19

Note : If the full payment has not been received on or before the date indicated, a further fee may be required which may be one of the following

  • the reinstatement fee;
  • the late payment fee; or
  • additional fee to reverse deemed expiry.

Please refer to the CIPO Patent Fees web page to see all current fee amounts.

Fee History

Fee Type Anniversary Year Due Date Paid Date
Advanced Examination 2023-12-19 2023-12-19
Reinstatement (national entry) 2023-12-19 2023-12-19
Request for examination - standard 2025-09-08 2023-12-19
Basic national fee - standard 2023-12-19 2023-12-19
MF (application, 2nd anniv.) - standard 02 2023-09-08 2023-12-19
Final fee - standard 2024-03-26
Excess claims (final fee) - standard 2024-07-25 2024-03-26
MF (patent, 3rd anniv.) - standard 2024-09-09 2024-08-08
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
WERTHENSTEIN BIOPHARMA GMBH
MERCK SHARP & DOHME LLC
Past Owners on Record
DIRK STUEBER
PATRICK LARPENT
RICHARD J. VARSOLONA
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Representative drawing 2024-02-01 1 7
Cover Page 2024-02-01 1 37
Description 2024-03-08 13 997
Claims 2024-03-08 4 188
Cover Page 2024-04-09 1 37
Representative drawing 2024-04-09 1 5
Abstract 2023-12-19 2 73
Description 2023-12-19 13 602
Claims 2023-12-19 6 91
Drawings 2023-12-19 4 59
Confirmation of electronic submission 2024-08-08 3 79
Courtesy - Advanced Examination Request - Compliant (SO) 2024-01-09 1 164
Examiner requisition 2024-01-23 3 166
Amendment / response to report 2024-03-08 17 873
Final fee 2024-03-26 4 136
Electronic Grant Certificate 2024-05-07 1 2,528
Commissioner's Notice - Application Found Allowable 2024-03-25 1 577
Courtesy - Letter Acknowledging PCT National Phase Entry 2024-01-04 1 596
Courtesy - Acknowledgement of Request for Examination 2024-01-04 1 422
Patent cooperation treaty (PCT) 2023-12-19 1 40
Patent cooperation treaty (PCT) 2023-12-20 2 172
National entry request 2023-12-19 12 452
International search report 2023-12-19 8 420
Declaration 2023-12-19 4 60
Third party observation 2023-12-19 2 66